1 Min Read
May 4 (Reuters) - Argenx Nv:
* Argenx NV - has recruited 50 pct of myasthenia gravis (mg) patients in phase 2 proof-of-concept study of argx-113 Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.